OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...

The show's unique combination of hands-on product and technology demonstrations, education and face-to-face connections makes Modex the can't-miss experience for supply chain professionals this year.

OPKO Health (NASDAQ:OPK) reported first-quarter 2026 results and highlighted continued progress across its ModeX Therapeutics ...

Flux Power Holdings, Inc . (NASDAQ: FLUX), a leading developer of advanced lithium-ion energy storage solutions and software for material handling and industrial applications, today announced it has ...

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301 for the prevention of COVID-19 ...

The big-time BARDA contracts keep rolling in, this time for infectious disease biotech and Merck partner ModeX Therapeutics. The company has hauled in a $168 million contract from the Biomedical ...

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas Preclinical studies presented at 2025 American Society of ...

Despite its long-standing presence, AI's true potential in supply chain management is only now being recognized.

Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executed Development ...